Novo Nordisk (NYSE:NVO) has successfully implemented a reduction in its share capital following shareholder approval at its Annual General Meeting on March 21, 2024.
The pharmaceutical giant has reduced its B share capital from DKK 343,512,800 to DKK 339,012,800, achieved through the cancellation of 45 million B shares, each with a nominal value of DKK 0.10.
This action has decreased the company’s total share capital to DKK 446,500,000, which is now divided into A shares totaling DKK 107,487,200 and B shares at DKK 339,012,800.
Despite the reduction, Novo Nordisk assured stakeholders that the move will not impact its ongoing share repurchase program, which will continue as planned.